Теоретичні засади формування структури мотиваційної ентропії

Надано авторське бачення структури мотиваційної ентропії, представлено схему формування мотиваційної ентропії та її вплив на виробничу поведінку

LC-MS/MS-based proteome profiling in Daphnia pulex and Daphnia longicephala: the Daphnia pulex genome database as a key for high throughput proteomics in Daphnia

<p>Abstract</p> <p>Background</p> <p>Daphniids, commonly known as waterfleas, serve as important model systems for ecology, evolution and the environmental sciences. The sequencing and annotation of the <it>Daphnia pulex </it>genome both open future avenues of research on this model organism. As proteomics is not only essential to our understanding of cell function, and is also a powerful validation tool for predicted genes in genome annotation projects, a first proteomic dataset is presented in this article.</p> <p>Results</p> <p>A comprehensive set of 701,274 peptide tandem-mass-spectra, derived from <it>Daphnia pulex</it>, was generated, which lead to the identification of 531 proteins. To measure the impact of the <it>Daphnia pulex </it>filtered models database for mass spectrometry based <it>Daphnia </it>protein identification, this result was compared with results obtained with the Swiss-Prot and the <it>Drosophila melanogaster </it>database. To further validate the utility of the <it>Daphnia pulex </it>database for research on other <it>Daphnia </it>species, additional 407,778 peptide tandem-mass-spectra, obtained from <it>Daphnia longicephala</it>, were generated and evaluated, leading to the identification of 317 proteins.</p> <p>Conclusion</p> <p>Peptides identified in our approach provide the first experimental evidence for the translation of a broad variety of predicted coding regions within the <it>Daphnia </it>genome. Furthermore it could be demonstrated that identification of <it>Daphnia longicephala </it>proteins using the <it>Daphnia pulex </it>protein database is feasible but shows a slightly reduced identification rate. Data provided in this article clearly demonstrates that the <it>Daphnia </it>genome database is the key for mass spectrometry based high throughput proteomics in <it>Daphnia</it>.</p

Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors

Vascular endothelial growth factor; Advanced solid tumors; NanobodyFactor de crecimiento endotelial vascular; Tumores sólidos avanzados; NanocuerpoFactor de creixement endotelial vascular; Tumors sòlids avançats; NanocosBackground BI 836880 is a humanized bispecific nanobody® that inhibits vascular endothelial growth factor and angiopoietin-2. Here, we report results from two phase I, nonrandomized, dose-escalation studies (NCT02674152 and NCT02689505; funded by Boehringer Ingelheim) evaluating BI 836880 in patients with confirmed locally advanced or metastatic solid tumors, refractory to standard therapy, or for which standard therapy was ineffective. Patients and Methods Patients aged ≥18 years, with an Eastern Cooperative Oncology Group performance status of 0-2 and adequate organ function received escalating intravenous doses of BI 836880 once every 3 weeks (Q3W; Study 1336.1) or once weekly (QW; Study 1336.6). Primary objectives were maximum tolerated dose (MTD) and recommended phase II dose of BI 836880, based on dose-limiting toxicities (DLTs) during the first cycle. Results Patients received one of five dosages of 40-1000 mg Q3W (29 patients) or 40-240 mg QW (24 patients). One DLT occurred with Q3W treatment [Grade (G) 3 pulmonary embolism (1000 mg)]. Five DLTs occurred in four patients treated QW [G2 proteinuria (120 mg); G3 hypertension (180 mg); G3 proteinuria and G3 hypertension (240 mg); and G4 respiratory distress (240 mg)]. All patients experienced adverse events, most commonly hypertension with Q3W treatment (89.7%; G3 41.4%), and asthenia with QW treatment (62.5%). Two patients treated Q3W (both 1000 mg) and three patients treated QW (120 mg, 2 patients; 180 mg, 1 patient) experienced partial response. Conclusions The MTD of BI 836880 was 720 mg Q3W and 180 mg QW. BI 836880 was generally manageable and demonstrated preliminary efficacy.This work was supported by Boehringer Ingelheim International GmbH. Medical writing support for the development of this manuscript, under the direction of the authors, was provided by Hannah Simmons, MSc, of Ashfield MedComms, an Ashfield Health company and funded by Boehringer Ingelheim

Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors

BACKGROUND: BI 836880 is a humanized bispecific nanobody® that inhibits vascular endothelial growth factor and angiopoietin-2. Here, we report results from two phase I, nonrandomized, dose-escalation studies (NCT02674152 and NCT02689505; funded by Boehringer Ingelheim) evaluating BI 836880 in patients with confirmed locally advanced or metastatic solid tumors, refractory to standard therapy, or for which standard therapy was ineffective. PATIENTS AND METHODS: Patients aged ≥18 years, with an Eastern Cooperative Oncology Group performance status of 0-2 and adequate organ function received escalating intravenous doses of BI 836880 once every 3 weeks (Q3W; Study 1336.1) or once weekly (QW; Study 1336.6). Primary objectives were maximum tolerated dose (MTD) and recommended phase II dose of BI 836880, based on dose-limiting toxicities (DLTs) during the first cycle. RESULTS: Patients received one of five dosages of 40-1000 mg Q3W (29 patients) or 40-240 mg QW (24 patients). One DLT occurred with Q3W treatment [Grade (G) 3 pulmonary embolism (1000 mg)]. Five DLTs occurred in four patients treated QW [G2 proteinuria (120 mg); G3 hypertension (180 mg); G3 proteinuria and G3 hypertension (240 mg); and G4 respiratory distress (240 mg)]. All patients experienced adverse events, most commonly hypertension with Q3W treatment (89.7%; G3 41.4%), and asthenia with QW treatment (62.5%). Two patients treated Q3W (both 1000 mg) and three patients treated QW (120 mg, 2 patients; 180 mg, 1 patient) experienced partial response. CONCLUSIONS: The MTD of BI 836880 was 720 mg Q3W and 180 mg QW. BI 836880 was generally manageable and demonstrated preliminary efficacy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.govNCT02674152; https://clinicaltrials.gov/ct2/show/NCT02674152 and NCT02689505; https://clinicaltrials.gov/ct2/show/NCT0268950

Drittes Stuttgarter Bildungsforum - Kolloquium 'Ingenieurausbildung im Umbruch' am 13. November 1998

Nach dem 1. und 2. Stuttgarter Bildungsforum in den Jahren 1993 und 1994 erscheint nun eine Fortsetzung, die sich speziell mit der Ingenieurausbildung auseinandersetzt. Der Workshop „Ingenieurausbildung im Umbruch“ am 13. November 1998 setzt den seinerzeit begonnenen Dialog zwischen Industrie, Politik sowie öffentlichen und privatrechtlichen Institutionen fort, bei dem die Erwartungen der Wirtschaft an künftige Universitätsabsolventen diskutiert worden sind. Dabei standen insbesondere die sogenannten „soft skills“ auf dem Prüfstand, d.h. die immer wieder von der Industrie eingeforderten Kompetenzen im fremdsprachlichen Bereich, in Präsentations- und Kommunikationstechniken, in Teamarbeit, in sozialem Engagement etc. Diese nicht-fachspezifischen Ausbildungsinhalte spielen offensichtlich im Zeitalter der Globalisierung, von stationären und temporären Joint Ventures, einer sich rasant entwickelnden Kommunikation wie auch des Internet eine immer größere Rolle. Die Universität Stuttgart stellt sich diesen Forderungen, indem die Studien- und Prüfungsordnungen der Ingenieurstudiengänge abgeprüft und dort, wo es sinnvoll erscheint, gewisse soft skills integriert werden. Es ist daran gedacht, diesen speziellen Dialog fortzuführen und in einem weiteren Workshop, der im November 1999 stattfinden soll, über erste Erfahrungen in der Implementierung berichten zu lassen

Entrepreneurial role models, fear of failure, and institutional approval of entrepreneurship: A tale of two regions

Studies on the influence of entrepreneurial role models (peers) on the decision to start a firm ar-gue that entrepreneurial role models in the local environment (1) provide opportunities to learn about entrepreneurial tasks and capabilities, and (2) signal that entrepreneurship is a favorable career option thereby reducing uncertainty that potential entrepreneurs face. However, these studies remain silent about the role of institutional context for these mechanisms. Applying an ex-tended sender-receiver model, we hypothesize that observing entrepreneurs reduces fear of fail-ure in others in environments where approval of entrepreneurship is high while this effect is signif-icantly weaker in low approval environments. Taking advantage of the natural experiment from recent German history and using data from the Global Entrepreneurship Monitor Project (GEM), we find considerable support for our hypotheses

Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications

This work was supported by a restricted research grant of Bayer AG